Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Liabilities and Shareholders Equity (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $271.7 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Liabilities and Shareholders Equity rose 41.07% year-over-year to $271.7 million, compared with a TTM value of $862.7 million through Dec 2023, up 10.44%, and an annual FY2022 reading of $287.0 million, up 70.78% over the prior year.
  • Liabilities and Shareholders Equity was $271.7 million for Q3 2023 at Terns Pharmaceuticals, down from $289.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $301.3 million in Q1 2023 and bottomed at $92.3 million in Q4 2020.
  • Average Liabilities and Shareholders Equity over 4 years is $205.9 million, with a median of $190.3 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity decreased 22.95% in 2022, then skyrocketed 99.98% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $92.3 million in 2020, then surged by 82.11% to $168.1 million in 2021, then surged by 70.78% to $287.0 million in 2022, then decreased by 5.34% to $271.7 million in 2023.
  • Business Quant data shows Liabilities and Shareholders Equity for TERN at $271.7 million in Q3 2023, $289.7 million in Q2 2023, and $301.3 million in Q1 2023.